提出了2种用于构建生物人工肾小管的中空纤维膜聚砜膜表面的观察的新方法。采用免疫荧光染色(immunofluorescence staining,IF)和原子力显微镜(atomic force microscopy,AFM)对中空纤维聚砜膜内和外壁进行观察研究。实验表明免疫荧光染...提出了2种用于构建生物人工肾小管的中空纤维膜聚砜膜表面的观察的新方法。采用免疫荧光染色(immunofluorescence staining,IF)和原子力显微镜(atomic force microscopy,AFM)对中空纤维聚砜膜内和外壁进行观察研究。实验表明免疫荧光染色方法简便快捷,图象清晰,AFM的分辨率高,图象清晰,是除扫描电镜(scanning electronic microscope,SEM)外的两种观察生物人工肾小管的简便可靠方法。普通显微镜观察不能观察到中空纤维聚砜膜形态,AFM简便,图象清晰,分辨率较高,并且可以观察立体三维形态。实验结果显示IF和AFM是观察生物人工肾小管的中空纤维膜聚砜膜表面的观察的新方法,并且简便使用,分辨率高,能观察三维结构。展开更多
Background The objective of this study was to assess the clinical safety and efficacy of vena cava filter （VCF） placement, with particular emphasis on the incidence and risk factors of inferior vena cava thrombosis ...Background The objective of this study was to assess the clinical safety and efficacy of vena cava filter （VCF） placement, with particular emphasis on the incidence and risk factors of inferior vena cava thrombosis （VCT） after VCF placement. Methods Clinical data of patients with venous thromboembolism （VTE）, with or without placement of VCF, were analyzed in a retrospective single-center audit of medical records from January 2005 to June 2009. The collected data included demographics, procedural details, filter type, indications, and complications. Results A total of 168 cases of VTE （82 with VCF; 86 without VCF） were examined. Over a median follow-up of 24.2 months, VCT occurred in 18 of 82 patients with VCFs （11 males, 7 females, mean age 55.4 years）. In 86 patients without VCFs, VCT occurred in only 6 individuals （4 males, 2 females） during the study period. VCT was observed more frequently in patients fitted with VCFs than in those without VCFs （22% vs. 7.0%）. Conclusions The incidence of VCT in patients with VTE after VCF implantation was 22% approximately. Anticoagulation therapy should be continued for all patients with VCF placement, unless there is a specific contraindication. Almost all instances of VCT in patients with VCF implants in our study occurred after stopping anticoagulation treatment. The use of VCFs is increasing, and more trials are needed to confirm their benefit and accurately assess their safety.展开更多
文摘Background The objective of this study was to assess the clinical safety and efficacy of vena cava filter （VCF） placement, with particular emphasis on the incidence and risk factors of inferior vena cava thrombosis （VCT） after VCF placement. Methods Clinical data of patients with venous thromboembolism （VTE）, with or without placement of VCF, were analyzed in a retrospective single-center audit of medical records from January 2005 to June 2009. The collected data included demographics, procedural details, filter type, indications, and complications. Results A total of 168 cases of VTE （82 with VCF; 86 without VCF） were examined. Over a median follow-up of 24.2 months, VCT occurred in 18 of 82 patients with VCFs （11 males, 7 females, mean age 55.4 years）. In 86 patients without VCFs, VCT occurred in only 6 individuals （4 males, 2 females） during the study period. VCT was observed more frequently in patients fitted with VCFs than in those without VCFs （22% vs. 7.0%）. Conclusions The incidence of VCT in patients with VTE after VCF implantation was 22% approximately. Anticoagulation therapy should be continued for all patients with VCF placement, unless there is a specific contraindication. Almost all instances of VCT in patients with VCF implants in our study occurred after stopping anticoagulation treatment. The use of VCFs is increasing, and more trials are needed to confirm their benefit and accurately assess their safety.
